The new instrument will be used for abdominal operations.
Singapore-listed medical investor The Trendlines Group has won a $3.2m funding to start marketing and distributing a new surgical instrument that will be used in abdominal operations.
The funding is directed to Trendlines' medical portfolio company Gordian Surgical, which developed TroClose1200. Gordian announced that it has already secured Food and Drug Administration regulatory clearance for the new instrument.
The development is to give surgeons “two-in-one” functionality: the device acts both as a trocar, through which surgical instruments enter the abdomen, and a device to close internal incisions made during surgery.
“Receiving FDA clearance is a huge milestone in Gordian’s strategic roadmap. The recent investment, led by B. Braun, allows us to move rapidly towards commercialization of our device in the U.S., Europe and other markets," Gordian Surgical CEO Zvi Pe’er said.
Do you know more about this story? Contact us anonymously through this link.